PYMXQ Stock UPDATES Polymedix Inc (PYMXQ) 0.0200 08/03/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Polymedix Inc (PYMXQ) 0.0200 $PYMXQ

Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013
M2 - Wed Jun 19, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dnrjr/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013" report to their offering. 'Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. M Scope - A snapshot of the global therapeutic scenario for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and unive

Global Respiratory Tract Infections Report - Pipeline Review, H1 2013 Edition
M2 - Thu Jun 06, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hml3h6/respiratory_tract) has announced the addition of the "Respiratory Tract Infections - Pipeline Review, H1 2013" report to their offering. 'Respiratory Tract Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Infections. Scope - A snapshot of the global therapeutic scenario for Respiratory Tract Infections. - A review of the Respiratory Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages.

Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development



Scroll down for more posts ▼

Top 10 Most Recent News Articles

SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 257

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 15

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 138

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 46

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 297

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 0

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 130

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
Ideas Abu Dhabi Puts Water Innovation on Stage

Updated Category News Views 25

Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 26

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading

Top 5 Most Recently Viewed Articles

Enhanced Insurance Solutions for Virginians Amid Rising Costs

Updated Category News Views 130

Understanding the Rising Costs of Bodily Injury Claims Bodily injury costs in Virginia are on the rise, impacting the financial health of many residents. Unforeseen incidents, from car accidents to dog bites, can swiftly escalate into significant financial burdens. Reports indicate that liability claims have surged, with the average payout increasing significantly since...

Continue Reading
Investors Notify: Class Action Suit Against Lockheed Martin

Updated Category News Views 245

Overview of the Class Action Lawsuit Bragar Eagel & Squire, P.C. has recently announced the initiation of a class action lawsuit against Lockheed Martin Corporation (NASDAQ: LMT). This lawsuit is intended for all individuals and entities that acquired Lockheed Martin securities during the designated class period, which spans from January 23, 2024, to July 21, 2025. The...

Continue Reading
Market Trends Lead MUJ Stock to New Yearly Low of $10.97

Updated Category News Views 186

Understanding the Decline of MUJ Stock In a challenging economic landscape, BlackRock's MuniHoldings New Jersey Quality Fund (MUJ) stock has faced significant declines, recently hitting a 52-week low of $10.97. This shift in value reflects broader market trends affecting municipal bond funds and investor sentiment towards interest rates and credit risk. Key Indicators Of...

Continue Reading
Public Service Company of New Mexico Announces Q1 Dividend

Updated Category News Views 92

Public Service Company of New Mexico Announces Quarterly Dividend The Board of Directors at Public Service Company of New Mexico, part of TXNM Energy (NYSE: TXNM), has officially declared its regular quarterly dividend. This announcement marks a continued commitment to returning value to shareholders. The declared dividend stands at $1.145 per share, attributed to the...

Continue Reading
Nations Photo Lab Earns Recognition for Premium Photo Services

Updated Category News Views 437

Nations Photo Lab Recognized for Outstanding Photo Services In an exciting development within the photo printing sector, Nations Photo Lab has been acknowledged as a leading provider of premium photo printing and framing services. This recognition highlights the increasing demand for unique and high-quality wall art in both residential and commercial spaces. The rise of...

Continue Reading